Blosozumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Blosozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetSOST
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6462H9852N1684O2030S46
Molar mass144.63 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.[2]

Blosozumab was developed by Eli Lilly and Company.

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[permanent dead link]
  2. ^ McColm, Juliet; Hu, Leijun; Womack, Theresa; Tang, Cheng Cai; Chiang, Alan Y (2014-04-01). "Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women". Journal of Bone and Mineral Research. 29 (4): 935–943. doi:10.1002/jbmr.2092. ISSN 1523-4681. PMID 23996473.